Panacea Life Sciences' premium CBD products first entered Denver International Airport in May 2021, taking advantage of the near record numbers of passenger traffic
GOLDEN, CO / ACCESSWIRE / October 29, 2021 / Exactus, Inc. (OTCQB:EXDI), soon to be Panacea Life Sciences, Inc. (OTCQB:PLSH)(Panacea) a cGMP certified, vertically integrated premium CBD company located in Golden, Colorado, plans to capitalize on Denver International Airport's (DEN) resurgence of air travelers. During the first half of 2021, nearly 25 million passengers traveled through the airport. This offers Panacea many opportunities for travelers to see, try, and buy CBD products at their two kiosk locations in DEN's B and C concourses.
The airport retail space has proven to be a big move for Panacea. Panacea's May entry marked the first time that CBD products have been made available for passengers and visitors at DEN and Panacea has been the perfect company to pioneer entry into this arena. Panacea is a seed-to-sale cannabinoid company with its roots planted at their farm on the western slope of Colorado and at their 51,000 square foot manufacturing facility in Golden. Travelers, whether coming, going, or just passing through, will be thrilled to find therapeutic relief that CBD can provide. Several studies have found that CBD and other cannabinoids have anti-inflammatory properties, so it is suitable to alleviate the stiff and sore muscles, aches, and pains that flying can bring about.
Panacea carries over 18 CBD products for topical use, including pain relief patches, heating and cooling balm sticks, lotions, lip balm and more. While some may be hesitant to purchase CBD while traveling, it's important to know that hemp-derived CBD products are legal in all 50 United States, as long as the products contain less than 0.3% THC - a rule which Panacea follows stringently. Additionally, the kiosks will sell personal protection equipment like masks and hand sanitizer for these on-the-go consumers.
Find Panacea's kiosk on the southwest side of the center of Concourse C and at their second location on the northeast side of the center of Concourse B.
Exactus, Inc. (OTCQB:EXDI) (the "Company"), acquired Panacea Life Sciences, Inc. on June 30, 2021. Panacea, which was founded by Leslie Buttorff in 2017 as a woman-owned business, has attracted $20 million in initial investments. In 2019, these were followed up with a $14 million investment from 22nd Century Group, Inc. (XXII), a leading plant biotechnology company focused on technology to decrease nicotine in tobacco plants and uses its expertise for genetic engineering of hemp plants to modify cannabinoid levels used in manufacturing CBD, CBG and CBN.
Panacea Life Sciences is a leader in production of legal, trace THC, hemp-derived cannabinoid products for consumers and pets that operates a 51,000 square foot cGMP certified facility in Golden, Colorado and the PANA Botanicals farm in western Colorado, complete with fully integrated extraction, manufacturing, testing and fulfillment. Panacea produces softgels, gummies, tinctures, sublingual tablets, cosmetics, and other topicals for purchase online (www.panacealife.com) and in stores as well as in smart kiosk vending machines being rolled out nationally.
If you would like more information about this topic or to learn more about Panacea and its products or our land-to-brand practices, please visit panacealife.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategic partnership with Denver International Airport, including the perceived merits and anticipated outcome of our new relationship, consumer demand for and suitability of our products in retail locations and in general, and the expected growth of the CBD/hemp industry in which we operate. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include the possibility that our partnership with Denver International Airport is not successful due to friction which may arise between the parties, regulatory challenges and, the risk that due to insufficient sales or for other reasons Denver International Airport discontinues selling Panacea's products. Other risks are included in filings with the SEC made by Exactus, Inc., parent company of Panacea. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
CONTACT:
Nick Cavarra
nick.cavarra@panacealife.com
SOURCE: Exactus Inc.
View source version on accesswire.com:
https://www.accesswire.com/670282/CBD-Company-Panacea-Life-Sciences-Sees-Promise-as-Denver-Airport-Reaches-Third-Highest-Passenger-Traffic-in-World
